Mr Matthew Frayne
ProImmune is your ideal strategic partner for managing the immunogenicity risk of biological drugs, the discovery of new antigens, e.g. for targeted sub-unit vaccines, and monitoring immune responses, such as cellular and humoral immune responses, with the most advanced technologies.
Whether you are looking to improve the specificity of your therapy, reduce unwanted immunogenicity or simply broaden your IP portfolio, we can provide all or any part of the solution.
Come and see us at booth #73
Mr Hans Glise
Almac provides a comprehensive range of integrated services from research through to commercialisation. Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.
Services Offered
Almac’s integrated solutions extend from research to commercialisation and include:
Biomarker Discovery & Development:
· Companion Diagnostic Development
· Genomic Services
· Bioinformatics Consultancy
· Proprietary Discovery Arrays
API Services & Chemical Development:
· API Development & Manufacture
· Peptide & Protein Technology
· Accelerated First in Man Solution
· Solid State Services
· Isotope Chemistry
· Biocatalysis
Pharmaceutical Development:
· Preformulation & Early Stage Development
· Scale Up and Late Stage Development
· Clinical Trial Manufacture
· Contained Development & Manufacture
Analytical Services:
· Physical & Chemical Characterisation
· Method Development & Validation
· API & Drug Product Testing
· Stability Testing
Clinical Trial Supply:
· Comparator Blinding
· Packaging & Labelling
· QP Release
· Global Distribution & Supply Chain Management
Clinical Technologies:
· IVR / Web
· ePRO
· Statistical Services
Commercial Services
· Manufacturing & Packaging
· Product Launch & Distribution
Come and see us at booth #70
Almac Group
Dr Cora Griffin
Q Chip is using a novel approach to encapsulate therapeutics in bioresorbable polymer microspheres for injection and sustained drug release (SR). We avoid the use of harsh solvents, high temperatures and shearing forces and achieve a tuneable output with high API loading and microsphere monodispersity, minimising production cost and controlling burst release.
We have demonstrated successful sustained release for peptide GnRH and SST agonists; the technology is also applicable for small and insoluble molecules. Through partnerships/collaborations, we are now exemplifying our platform in a range of therapeutic areas, both for NCEs and generics.
Q Chip's Dutch site (Q Chip BV) opened in 2011; this new facility will be used for the GMP manufacture of clinical trial material.
Q Chip's technology platform Q-Sphera is based on the use of benign encapsulation and desolvation conditions to create highly monodisperse microspheres of bioresorbable polymer containing drug. The technology lends itself to the rapid development of novel SR formulations, the encapsulation of conventional NCEs (small molecules, peptides) as well as life cycle management and generics development.
Dr Rob Grundy
Almac provides a comprehensive range of integrated services from research through to commercialisation. Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.
Services Offered
Almac’s integrated solutions extend from research to commercialisation and include:
Biomarker Discovery & Development:
· Companion Diagnostic Development
· Genomic Services
· Bioinformatics Consultancy
· Proprietary Discovery Arrays
API Services & Chemical Development:
· API Development & Manufacture
· Peptide & Protein Technology
· Accelerated First in Man Solution
· Solid State Services
· Isotope Chemistry
· Biocatalysis
Pharmaceutical Development:
· Preformulation & Early Stage Development
· Scale Up and Late Stage Development
· Clinical Trial Manufacture
· Contained Development & Manufacture
Analytical Services:
· Physical & Chemical Characterisation
· Method Development & Validation
· API & Drug Product Testing
· Stability Testing
Clinical Trial Supply:
· Comparator Blinding
· Packaging & Labelling
· QP Release
· Global Distribution & Supply Chain Management
Clinical Technologies:
· IVR / Web
· ePRO
· Statistical Services
Commercial Services
· Manufacturing & Packaging
· Product Launch & Distribution
Come and see us at booth #70
Mr Colin Hayburn
Almac provides a comprehensive range of integrated services from research through to commercialisation. Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.
Services Offered
Almac’s integrated solutions extend from research to commercialisation and include:
Biomarker Discovery & Development:
· Companion Diagnostic Development
· Genomic Services
· Bioinformatics Consultancy
· Proprietary Discovery Arrays
API Services & Chemical Development:
· API Development & Manufacture
· Peptide & Protein Technology
· Accelerated First in Man Solution
· Solid State Services
· Isotope Chemistry
· Biocatalysis
Pharmaceutical Development:
· Preformulation & Early Stage Development
· Scale Up and Late Stage Development
· Clinical Trial Manufacture
· Contained Development & Manufacture
Analytical Services:
· Physical & Chemical Characterisation
· Method Development & Validation
· API & Drug Product Testing
· Stability Testing
Clinical Trial Supply:
· Comparator Blinding
· Packaging & Labelling
· QP Release
· Global Distribution & Supply Chain Management
Clinical Technologies:
· IVR / Web
· ePRO
· Statistical Services
Commercial Services
· Manufacturing & Packaging
· Product Launch & Distribution
Come and see us at booth #70
Almac Group
Dr Guy Hill
Arecor enables biologics to be more stable; highly-concentrated; and durable to temperature. Arecor has a proprietary and patented technology platform for improving the stability of a range of therapeutic proteins including vaccines.
Dr Catherine Hunter
CrystecPharma applies the latest supercritical fluid technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies. Crystec supercritical fluid technologies can be applied to both small drug molecules and biotechnologically sourced drugs.
Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.
Come and see us at booth #73
Mr Gordon Kennovin
Aptuit is a global pharmaceutical services company that delivers early to mid-phase drug development solutions to more than 800 companies by applying scientific excellence, outstanding service and a team of some of the foremost scientific professionals in the industry. From seven locations around the world, including our strategic partner in India, Aptuit assists clients by shortening their timelines and delivering on time, in full. We solve scientific problems through technical expertise and superior project management. We provide significant value to our clients by delivering high quality services that exceed regulatory compliance standards.
Aptuit services include:
• Drug Design & Discovery
• Preclinical Biosciences
• API Development and Manufacture
• Solid State Chemistry
• Solid, Oral and Sterile Dosage Form Development and Manufacture
• Clinical Sciences
• Consulting
• Aptuit INDiGO® - Accelerated Drug Development Program
• Integrated Drug Discovery and Development
Aptuit (Glasgow) are specialist providers of formulation development and GMP manufacture of sterile dosage products, both liquid and lyophilised, for use within pre-clinical and clinical trials.
Our dedicated formulation scientists are experts in the delivery of complex formulations for liquid and lyophilised product types for small organic molecules through to large macromolecules (peptides, proteins, oligonucleotides etc). This is supported by a team of dedicated analytical scientist who are able to develop, validate or transfer analytical methods for use in the development of the formulation.
Mrs Heidi Kingdon-Jones
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services.
For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCINGTM, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline.
AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development.
Mr Michael Kruidenier
Penn is a provider of an integrated range of services to the global pharmaceutical industry. They provide consultancy on matters relating to CMC data and the role of the QP. Their core services are Pre-formulation studies, Formulation Development including expertise in poorly soluble molecules, Analytical Services including stability testing, Clinical Trials Supplies from phase I-IV and commercial supply. Penn is a leading provider of Hi Contaiment Solid Oral Dose Manufacturing and for clinical trial manufacturing/packing/labelling/distribution services. Penn has been FDA inspected 9 times in recent years and has 7 QPs on site.
Their product offer and experience is wide - including solid dose forms, liquids, semi solids and high containment processing. Dedicated Phase I and ISS teams
Penn services include:
CMC Consultancy, Formulation Development, Analytical Development, Clinical Trial Supply, Contract Manufacturing, Qualified Persons Release Services, Paediatrics Formulation and Manufacturing, Hi-Potency capabilities, Orphan drug expertise, More than 30 Years of specials, manufacturing expertise, Comparator Sourcing.
The above offerings are all under one roof providing a strong and easy communication channel between departments making developments, manufacturing and analytical processes.
Come and see us at booth #73